SCHEMBL3292268

SCHEMBL3292268

Cc1c(Cl)cccc1S(=O)(=O)Nc1cc2cncnc2nc1OCc1ccc2c(c1)OCCN2C

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.49
▸ PTGES2 Q9H7Z7 1/20 0.39
▸ PDE10A Q9Y233 1/20 0.38
▸ CCR4 P51679 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ EIF2AK3 Q9NZJ5 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ SLC40A1 Q9NP59 1/20 0.36
▸ PDCD1 Q15116 2/20 0.36
▸ CD274 Q9NZQ7 2/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3293196 0.95 TP53 (0.48) TP53PTGES2CCR4TDP1HSD11B1
SCHEMBL3291311 0.90 TP53 (0.53) TP53PTGES2PDE10ACCR4TDP1
SCHEMBL3292229 0.89 TP53 (0.46) TP53PTGES2PDE10ACCR4TDP1
SCHEMBL3291703 0.89 TP53 (0.49) TP53PTGES2PDE10ACCR4TDP1
SCHEMBL3293318 0.87 TP53 (0.51) TP53PTGES2CCR4TDP1EIF2AK3
SCHEMBL3290886 0.87 TP53 (0.52) TP53PTGES2CCR4TDP1EIF2AK3
SCHEMBL3298590 0.85 TP53 (0.52) TP53PTGES2CCR4HSD11B1SLC40A1
SCHEMBL3293488 0.84 TP53 (0.45) TP53PDE10ACCR4TDP1HSD11B1
SCHEMBL3290769 0.84 TP53 (0.51) TP53PTGES2CCR4TDP1EIF2AK3
SCHEMBL3295404 0.84 TP53 (0.53) TP53PTGES2CCR4TDP1EIF2AK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-21 — — US disclosed
US-7732442-B2 Chemokine receptor antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 — — US disclosed
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 — — US disclosed
EP-1661889-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF CCR5, CCR4, CCR1 TP53 2581/4885PTGES2 1314/4885PDE10A 1665/4885
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof CCR5, CCR4, CCR1 TP53 2581/4885PTGES2 1314/4885PDE10A 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback